Hodgkin Lymphoma (HL)

Overview

Hodgkin lymphoma (HL) is a B-cell-derived lymphoid malignancy characterized by malignant Reed-Sternberg cells embedded in an inflammatory background. It is classified into classical HL (nodular sclerosis, mixed cellularity, lymphocyte-rich, lymphocyte-depleted) and nodular lymphocyte-predominant HL. HL is highly curable in most patients with chemotherapy (ABVD) and/or radiotherapy. Relapsed/refractory HL is increasingly treated with brentuximab vedotin and checkpoint inhibitors (nivolumab, pembrolizumab).

Cohorts in the corpus

  • mixed_pipseq_2017 — PIPseq pediatric pan-cancer cohort (Columbia University Medical Center), which includes Hodgkin lymphoma cases among 101 high-risk pediatric patients PMID:28007021.

Recurrent alterations

  • PIPseq cohort: ITK V175V variant of uncertain significance (VOUS) returned in one Hodgkin lymphoma patient who also had EBV infection; the variant’s functional significance in this context was not established PMID:28007021.

Subtypes

  • Classical HL: nodular sclerosis (most common), mixed cellularity, lymphocyte-rich, lymphocyte-depleted.
  • Nodular lymphocyte-predominant HL (NLPHL): distinct biology with LP (“popcorn”) cells.

Therapeutic landscape

  • Standard treatment: ABVD chemotherapy; radiotherapy for localized disease.
  • Relapsed/refractory: brentuximab vedotin (anti-CD30 ADC), nivolumab, pembrolizumab.

Sources

  • PMID:28007021 — Oberg et al. PIPseq pediatric pan-cancer sequencing program (n=101).

This page was processed by crosslinker on 2026-05-14.